JP5814851B2 - 関節炎の全身処置のための組成物および方法 - Google Patents
関節炎の全身処置のための組成物および方法 Download PDFInfo
- Publication number
- JP5814851B2 JP5814851B2 JP2012088149A JP2012088149A JP5814851B2 JP 5814851 B2 JP5814851 B2 JP 5814851B2 JP 2012088149 A JP2012088149 A JP 2012088149A JP 2012088149 A JP2012088149 A JP 2012088149A JP 5814851 B2 JP5814851 B2 JP 5814851B2
- Authority
- JP
- Japan
- Prior art keywords
- sojia
- receptor
- patients
- arthritis
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
Description
Cassidy,JT and Ross,E.2001,Text Book of Pediatric Rheumatology,第4版,Books on Demand Publishers,Visby,Sweden;218−321ページ Yokata,S.2003,"Interleukin 6 as a therapeutic target in sytemic−onset juvenile idiopathic arthritis",Curr Opin.Rheumatol 15:581−586 de Benedetti F.et al.,1991,Arthritis Rheum 34:1158−1163 Mangge,H,et al.,1999.J.Interferon Cytokine Res 19:1005−1010 Ozen S,et al.,1997.Clin Rheumatol 16:173−178 de Benedetti F.et al.,1999.J Rheumatol 26:425−431 Muller K,et al.1998.Br J Rheumatol 37:562−569 Shahin A et al.,2002.Rheumatol Int 22:84−88 de Benedetti F,et al.,1992.Clin Exp Rheumatol 10:493−498 Muzaffer M.et al.,2002.J.Rheumatol 29:1071−1078 Lomater C,et al.,2000,J.Rheunmatol 27:491−496
従って、SOJIAは特定の処置が決定されていない未知病因の慢性炎症性疾患のままである。広範な研究にもかかわらず、SOJIAを患う患者の複数薬による処置は、少数関節炎及び多発性関節炎のものと同様であり、それは疾患の相(全身相に対する関節炎相)および関与の範囲に依存する。少数の患者は、非ステロイド系抗炎症薬(NSAID)で軽快するが、大部分の小児は症状を制御するために経口および/または非経口ステロイドならびにメトトレキセート(methotrexate)の使用を必要とする。静脈内免疫グロブリン(IVIG)は、治療に不応性の場合に使用されている。最近では、抗TNF治療(例えばエタネルセプト(etanercept)およびインフリキシマブ(infliximab)がそれらの治療法に加えられた。それにもかかわらず、それらの医薬に関連するいくつかの限界および危険がある。例えば、免疫抑制性医薬、例えばメトトレキセートおよびステロイドを用いるそれら患者の長期処置は、ウイルス感染を排除する患者の能力の障害と関連があると報告されている。静脈内免疫グロブリン処置は、血液誘導製品の輸液と関連する危険を伴う。本発明は、SOJIA患者が同様に反応せずそして症状を制御するためにJIAの他の型よりも高い抗TNF作用物質の投与を必要とすることを発見した。従って、SOJIA疾患に対する効果的な薬剤効果の検証に対する継続的な要求がある。
本発明の各種の態様の構成および使用は以下に詳細に考察されるが、本発明は、各種の特定範囲のなかで実現できる多数の適用可能な発明性概念を提供することが認められなければならない。本明細書中で考察する特定の態様は、本発明の構成および使用のための特定の方向を単に説明するものであって、本発明の範囲を制限するものではない。
Claims (4)
- インターロイキン−1β(IL−1β)とIL−1β受容体との間の相互作用を遮断するインターロイキン−1(IL−1)受容体アンタゴニストタンパク質からなる、IL−1βの生物学的利用能を低下させる1種もしくはそれ以上の活性作用物質を有効成分として含んでなる、全身発症若年性特発性関節炎(SOJIA)を伴う小児患者を処置するための製薬学的製剤であって、前記IL−1受容体アンタゴニストタンパク質が、IL−1βを中和する抗体又はIL−1β受容体を遮断する抗体である、製薬学的製剤。
- IL−1受容体アンタゴニストタンパク質が、1〜250mg/日で供与される、請求項1に記載の製薬学的製剤。
- IL−1受容体アンタゴニストタンパク質が、IL−1βを中和する抗体である、請求項1に記載の製薬学的製剤。
- IL−1受容体アンタゴニストタンパク質が、IL−1β受容体を遮断する抗体である、請求項1に記載の製薬学的製剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54803304P | 2004-02-26 | 2004-02-26 | |
US60/548,033 | 2004-02-26 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007501027A Division JP4989456B2 (ja) | 2004-02-26 | 2005-02-25 | 関節炎の全身処置のための組成物および方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015143048A Division JP2015227356A (ja) | 2004-02-26 | 2015-07-17 | 関節炎の全身処置のための組成物および方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012162552A JP2012162552A (ja) | 2012-08-30 |
JP5814851B2 true JP5814851B2 (ja) | 2015-11-17 |
Family
ID=34910974
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007501027A Active JP4989456B2 (ja) | 2004-02-26 | 2005-02-25 | 関節炎の全身処置のための組成物および方法 |
JP2012088149A Active JP5814851B2 (ja) | 2004-02-26 | 2012-04-09 | 関節炎の全身処置のための組成物および方法 |
JP2015143048A Pending JP2015227356A (ja) | 2004-02-26 | 2015-07-17 | 関節炎の全身処置のための組成物および方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007501027A Active JP4989456B2 (ja) | 2004-02-26 | 2005-02-25 | 関節炎の全身処置のための組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015143048A Pending JP2015227356A (ja) | 2004-02-26 | 2015-07-17 | 関節炎の全身処置のための組成物および方法 |
Country Status (9)
Country | Link |
---|---|
US (13) | US7615212B2 (ja) |
EP (2) | EP1720893B1 (ja) |
JP (3) | JP4989456B2 (ja) |
CN (1) | CN1946734B (ja) |
AU (2) | AU2005216298B2 (ja) |
CA (1) | CA2557508C (ja) |
DK (1) | DK1720893T3 (ja) |
ES (1) | ES2523147T3 (ja) |
WO (1) | WO2005082070A2 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2349137T3 (es) * | 2000-06-20 | 2010-12-28 | Dainippon Sumitomo Pharma Co., Ltd. | Preparación para transferir oligonucleótidos. |
DK1407787T3 (da) * | 2001-06-20 | 2009-06-02 | Dainippon Sumitomo Pharma Co | Fremgangsmåde til fremme af nukleinsyreoverförsel |
ES2523147T3 (es) * | 2004-02-26 | 2014-11-21 | Baylor Research Institute | Composiciones y métodos para el tratamiento sistémico de la artritis |
PL2848258T3 (pl) * | 2005-10-26 | 2018-06-29 | Novartis Ag | Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta |
EP2152308A1 (en) * | 2007-05-29 | 2010-02-17 | Novartis Ag | New indications for anti- il-i-beta therapy |
US9028553B2 (en) | 2009-11-05 | 2015-05-12 | DePuy Synthes Products, Inc. | Self-pivoting spinal implant and associated instrumentation |
HUE026295T2 (en) | 2010-10-12 | 2016-06-28 | The Medicines Co | Clevidipine emulsion formulations containing antimicrobial agents |
US10966843B2 (en) | 2017-07-18 | 2021-04-06 | DePuy Synthes Products, Inc. | Implant inserters and related methods |
US11045331B2 (en) | 2017-08-14 | 2021-06-29 | DePuy Synthes Products, Inc. | Intervertebral implant inserters and related methods |
KR20220029665A (ko) * | 2019-07-02 | 2022-03-08 | 오하이오 스테이트 이노베이션 파운데이션 | 피부-뇌 축을 활용한 신경 퇴행성 질환 요법 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
US6159460A (en) | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
US6413511B1 (en) | 1990-12-20 | 2002-07-02 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide |
US6156304A (en) | 1990-12-20 | 2000-12-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene transfer for studying and treating a connective tissue of a mammalian host |
EP0547699A1 (en) | 1991-12-19 | 1993-06-23 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
DE69320176T2 (de) | 1992-02-21 | 1999-04-08 | Merck & Co Inc | Peptidylderivate und inhibitoren des interleukin-1-g(b)-konvertierenden enzyms |
DE69408598T2 (de) | 1993-06-08 | 1998-09-17 | Vertex Pharmaceuticals Inc Cam | Pyridazine als Interleukin-1-beta Verwandlungsenzym Inhibitoren |
US5747072A (en) | 1993-07-30 | 1998-05-05 | University Of Michigan | Adenoviral-mediated gene transfer to synovial cells in vivo |
CA2155929A1 (en) * | 1993-12-14 | 1995-06-22 | Christopher H. Evans | Systemic gene treatment of connective tissue diseases |
EP0688274B1 (fr) * | 1994-01-12 | 1997-09-10 | Valeo Vision | Corps d'allumage pour allume-cigares notamment de vehicule automobile |
US6268140B1 (en) | 1994-02-03 | 2001-07-31 | Neugenesis | Combinatorial metabolic libraries |
IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
US6573366B1 (en) | 1996-06-07 | 2003-06-03 | Gruppo Lepetit S.P.A. | Process for the purification of human interleukin-1 receptor antagonist from recombinant E. coli |
US5780513A (en) | 1996-08-22 | 1998-07-14 | Washington University | Method of inhibiting the release of bioactive IL-1 |
US6197551B1 (en) | 1998-01-27 | 2001-03-06 | Millennium Pharmaceuticals, Inc. | Spoil-1 protein and nucleic acid molecules and uses therefor |
GB9711040D0 (en) | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
DE19741051A1 (de) * | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
US5992573A (en) | 1997-09-24 | 1999-11-30 | Blain; Roy W. | Elevator up start |
US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
US7151082B2 (en) | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
AU775140B2 (en) * | 1999-03-18 | 2004-07-22 | Brigham And Women's Hospital | Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response |
WO2001087328A2 (en) | 2000-05-12 | 2001-11-22 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
UA80091C2 (en) * | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
IL161968A0 (en) * | 2001-11-14 | 2005-11-20 | Centocor Inc | Anti-il-6 antibodies, compositions, methods and uses |
KR101019131B1 (ko) * | 2001-11-19 | 2011-03-07 | 인터레우킨 제네틱스, 인코포레이티드 | 염증성 질환 및 감염성 질환에 대한 감수성 및 전사에영향을 미치는 인터루킨-1 좌의 기능적 다형성 |
US7337492B2 (en) * | 2002-07-25 | 2008-03-04 | Toshiba Tec Kabushiki Kaisha | Vacuum cleaner having a noise blocking member facing an intake vent of a motor fan |
ES2523147T3 (es) * | 2004-02-26 | 2014-11-21 | Baylor Research Institute | Composiciones y métodos para el tratamiento sistémico de la artritis |
MXPA06014126A (es) * | 2004-06-04 | 2007-07-18 | Regeneron Pharma | Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias. |
US7466175B2 (en) | 2006-12-29 | 2008-12-16 | Motorola, Inc. | Capacitance multiplier circuit |
-
2005
- 2005-02-25 ES ES05723881.8T patent/ES2523147T3/es active Active
- 2005-02-25 US US11/067,335 patent/US7615212B2/en active Active
- 2005-02-25 EP EP05723881.8A patent/EP1720893B1/en active Active
- 2005-02-25 CN CN2005800128324A patent/CN1946734B/zh active Active
- 2005-02-25 CA CA2557508A patent/CA2557508C/en active Active
- 2005-02-25 EP EP14173970.6A patent/EP2784090A1/en not_active Withdrawn
- 2005-02-25 AU AU2005216298A patent/AU2005216298B2/en active Active
- 2005-02-25 JP JP2007501027A patent/JP4989456B2/ja active Active
- 2005-02-25 DK DK05723881.8T patent/DK1720893T3/en active
- 2005-02-25 WO PCT/US2005/006200 patent/WO2005082070A2/en active Application Filing
-
2007
- 2007-10-26 US US11/925,555 patent/US20080161424A1/en not_active Abandoned
- 2007-10-26 US US11/925,568 patent/US7622110B2/en active Active
- 2007-10-26 US US11/925,538 patent/US20080161262A1/en not_active Abandoned
-
2009
- 2009-09-29 US US12/568,933 patent/US8148346B2/en active Active
- 2009-10-13 US US12/578,332 patent/US8221748B2/en active Active
-
2010
- 2010-08-25 AU AU2010214641A patent/AU2010214641C1/en active Active
-
2012
- 2012-02-28 US US13/407,362 patent/US20120148498A1/en not_active Abandoned
- 2012-04-09 JP JP2012088149A patent/JP5814851B2/ja active Active
- 2012-06-19 US US13/527,233 patent/US20120258120A1/en not_active Abandoned
-
2014
- 2014-02-07 US US14/175,686 patent/US20140364327A1/en not_active Abandoned
-
2015
- 2015-07-17 JP JP2015143048A patent/JP2015227356A/ja active Pending
- 2015-11-16 US US14/942,841 patent/US9649361B2/en active Active
-
2017
- 2017-04-17 US US15/488,764 patent/US10716832B2/en active Active
-
2020
- 2020-07-20 US US16/947,126 patent/US11406688B2/en active Active
-
2022
- 2022-08-08 US US17/818,276 patent/US20230134568A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5814851B2 (ja) | 関節炎の全身処置のための組成物および方法 | |
Feldmann et al. | Anti-TNFα therapy of rheumatoid arthritis: what have we learned? | |
Colmegna et al. | Current understanding of rheumatoid arthritis therapy | |
Taylor | Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases | |
Macías et al. | Modification of pro-and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. | |
RU2530561C2 (ru) | Способы лечения склеродермии | |
TW202106712A (zh) | 類風溼性關節炎之診斷及治療方法 | |
AU2012244136A1 (en) | Compositions and methods for the systemic treatment of arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130708 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130930 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131203 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20140528 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140807 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140812 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150420 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150717 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150903 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150918 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5814851 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |